LAVAL, Quebec, May 23, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Walmart, one of Valeant's largest customers, has presented Bausch + Lomb  with a Supplier of the Year Award for U.S. Manufacturing in the Consumables and Health & Wellness areas. Bausch + Lomb, which includes the Valeant Consumer Healthcare portfolio and businesses, is the largest global provider of eye care products.

The award, which was presented at Walmart's annual supplier summit, recognized Valeant's significant current and long-term investment plans in its U.S. manufacturing facilities – specifically the Bausch + Lomb sites in Greenville, S.C. and Tampa – and acknowledged Valeant's investment in the Bausch + Lomb contact lens manufacturing facility in Rochester, N.Y.

"We take pride in our ability to develop and introduce products that consumers want and need, and on our speed-to-market capabilities," said Joe Gordon, Senior Vice President and General Manager, Consumer Healthcare.  "Being recognized by Walmart as a top supplier is a true honor, and we look forward to additional growth and success with Walmart, our division's largest customer."  

"I want to extend my sincere appreciation to our local Walmart team and our cross-functional teams for their support and focus on Walmart.  Thanks to their efforts, our investments in U.S. manufacturing, solid service levels, and broad portfolio of strong consumer brands have not gone unnoticed by Walmart," said Gordon.

About Bausch + Lomb

Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries.

About Valeant Consumer Healthcare

Valeant has built one of the fastest growing consumer healthcare businesses in the U.S. based on retail sales. Valeant Consumer Healthcare offers a wide range of consumer healthcare products that improve the quality of everyday life:

  • Eye care: Includes lens care solutions Biotrue® Multi-Purpose Solution, PeroxiClear® hydrogen peroxide   solution and renu® fresh™ multi-purpose solutions; Soothe XP® eye drops for dry eye, Alaway® eye drops, TheraPearl® Eye Mask
  • Skin care: Includes the CeraVe® moisturizer and AMBI lines, as well as the AcneFree ® line. 
  • Vitamins: Includes Ocuvite® and PreserVision® eye vitamin and mineral supplements  

In addition to our product portfolio, Valeant Consumer Healthcare has a rich pipeline that relies on a research strategy that includes new formulations for existing products and line extensions, among others.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:

Laurie W. Little 
949-461-6002 
laurie.little@valeant.com

Elif McDonald
905-695-7607
elif.mcdonald@valeant.com

Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080

Valeant Pharmaceuticals International, Inc.

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bausch--lomb-wins-walmart-supplier-of-the-year-award-300272855.html

SOURCE Valeant Pharmaceuticals International, Inc.

Copyright 2016 PR Newswire

Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Valeant Pharma Charts.
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Valeant Pharma Charts.